Chemotherapy side effects on skin and mucous membranes;Chemotherapie-nebenwirkungen an haut und schleimhäuten

Praxis

Volumn 91, Issue 24, 2002, Pages 1078-1087

  Trojan, A ^a   Borelli, S ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

Chemotherapy; Mucocutaneous side effect

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; ARABINOSIDE; ASPARAGINASE; BUSULFAN; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; IDARUBICIN; LOMUSTINE; MELPHALAN; MERCAPTOPURINE; MITHRAMYCIN; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PROCARBAZINE; TENIPOSIDE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

ALOPECIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL FEATURE; HAND FOOT SYNDROME; HIDRADENITIS; HUMAN; HYPERPIGMENTATION; HYPERSENSITIVITY; MUCOSA; NAIL DISEASE; REVIEW; SKIN DISEASE; STOMATITIS; ULTRAVIOLET RADIATION;

EID: 0037067125     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/0369-8394.91.24.1078     Document Type: Review

References (32)

1. Bertelli, G. Prevention and management of extravasation of cytotoxic drugs. Drug Saf 1995;12: 245-55.
2. Margulies, A, Fellinger, K, Kroner, Th, Gaisser, A. Onkologische Krankenpflege. Springer 2001.
3. Cicchetti, S., Jemec, B., Gault, D. T. Two case reports of vinorelbine extravasation: management and review of the literature. Tumori 2000;86:289-92.
4. Herrington, J. D., Figneroa, J. A. Severe necrosis due to paclitaxel extravasation. Pharmacotherapy 1997;17:163-5.
5. Dorr, R. Antidotes to vesicant chemotherapy of extravasations. Blood Rev 1990;4:41-60.
6. Tosi, A., Misciali, C., Piraccini, B. M., Peluso, A. M., Bardazzi, F. Drug-induced hair loss and hair growth. Incidence, management and avoidance. Drug Saf 1994;10:310-7.
7. Pillans, P, Woods, D. Drug-associated alopecia. Int J Dermatol 1995;34:134-58.
8. Baker, B, Wilson, C, Davis, A, et al. Busulphan/cyclophosphamide conditioning for bone marrow transplantation may lead to failure of hair regrowth. Bone Marrow Transplant 1991;7:43-7.
9. Berger, A, Kilroy, T. Oral complications of cancer therapy. In:Cancer: principles and practice of oncology.Philadelphia: Lippincott. 2001;2881-93.
10. Evans, W. E., Pratt, C. B. Effect of pleural effusion on high-dose methotrexate kinetics. Clin.Pharmacol.Ther. 1978;23:68-72.
11. Mahood, D. J., Dose, A.M., Loprinzi, C. L., Veeder, M. H., Athmann, L. M., Therneau, T. M. et al. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin.Oncol. 1991;9:449-52.
12. Gruchalla, R. S. Drug metabolism, danger signals, and drug-induced hypersensitivity. J .Allergy Clin.Immunol. 2001;108:475-88.
13. Koppel, R. A., Boh, E. E. Cutaneous reactions to chemotherapeutic agents. Am.J Med.Sci. 2001;321:327-35.
14. Susser, W. S., Whitaker-Worth, D. L., Grant-Kels, J. M. Mucocutaneous reactions to chemotherapy. J Am.Acad.Dermatol 1999;40:367-98.
15. Bader, U., Banyai, M., Boni, R., Burg, G., Hafner, J. Leg ulcers in patients with myeloproliferative disorders: disease- or treatment-related? Dermatology 2000;200:45-8.
16. Fitzpatrick, J. E, Yokel, B. E, Hood, A. F. Mucocutaneous complications of antineoplastic therapy. Chapter 1997;2:1642-53.
17. Vassallo, C., Brazzelli, V., Ardigo, M., Borroni, G. The irreplaceable image: Nails changes in oncohematologic patients. Haematologica 2001;86:334-6.
18. Yeo, W., Johnson, P. J. Radiation-recall skin disorders associated with the use of antineoplastic drugs. Pathogenesis, prevalence, and management. Am.J.Clin.Dermatol. 2000;1:113-6.
19. Giesel, B. U., Kutz, G. G., Thiel, H. J. [Recall dermatitis caused by re-exposure to docetaxel following irradiation of the brain. Case report and review of the literature]. Strahlenther.Onkol. 2001;177:487-93.
20. Sauter, C. [«Radiation recall»]. Schweiz.Med.Wochenschr. 1997;127:2098.
21. Allen, J. E. Drug-induced photosensitivity. Clin.Pharm. 1993;12:580-7.
22. Gould, J. W., Mercurio, M. G., Elmets, C. A. Cutaneous photosensitivity diseases induced by exogenous agents. J Am.Acad.Dermatol 1995;33:551-73.
23. Nabai, H., Mohindra, R., Mehregan, D. Selective inflammatory effect of systemic fluorouracil in actinic keratosis. Cutis 1999;64:43-4.
24. Zuehlke, R. L. Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica 1974;148:90-2.
25. Burg, G., Bieber, T., Langecker, P. [Localized neutrophilic eccrine hydradenitis in mitoxantrone therapy: a typical side-effect of cytostatic drugs]. Hautarzt 1988;39:233-6.
26. Horn, T. D., Redd, J. V., Karp, J. E., Beschorner, W. E., Burke, P. J., Hood, A. F. Cutaneous eruptions of lymphocyte recovery. Arch.Dermatol 1989;125:1512-7.
27. Bauer, D. J., Hood, A. F., Horn, T. D. Histologic comparison of autologous graft-vs-host reaction and cutaneous eruption of lymphocyte recovery. Arch.Dermatol 1993;129:855-8.
28. Wilkin, J. K. Flushing reactions in the cancer chemotherapy patient. The lists are longer but the strategies are the same. Arch.Dermatol 1992;128:1387-9.
29. Miller, K. D., Picus, J., Blanke, C., John, W., Clark, J., Shulman, L. N. et al. Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann.Oncol. 2000;11:101-3.
30. Mokbel, K., Hassanally, D. From HER2 to herceptin. Curr.Med.Res.Opin. 2001;17:51-9.
31. Tobinai, K. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan. Cancer Chemother.Pharmacol. 2001;48 Suppl 1:S85-S90.
32. Brouard, M., Saurat, J. H. Cutaneous reactions to STI571. N.Engl.J.Med. 2001;345:618-9.